Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > LATEST
LATEST
-
REGULATORY Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
-
BUSINESS Novo Expands Oral Obesity Arsenal, Hengrui Asset Eyed around 2030
October 1, 2026
-
BUSINESS Bayer Takes Dialogue-Driven Innovation Model Nationwide
October 1, 2026
-
BUSINESS Chugai to Set Up South Korea Unit, Take Sales In-House
October 1, 2026
-
BUSINESS Daito Reveals Meiji, DBJ as Partners in Kyorin Generics JV
October 1, 2026
-
BUSINESS Sumitomo Universal Flu Vaccine Shows Favorable Safety in Europe PI
October 1, 2026
-
BUSINESS Rohto Wins Japan Sales Rights to PharmaBio’s Cell Sheet
October 1, 2026
-
REGULATORY Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
-
BUSINESS Asahi Kasei Rebrands Pharma Units under Common Global Name
September 30, 2026
-
ORGANIZATION JPMA to Complete Shift to Legal Entity on October 1
September 30, 2026
-
BUSINESS Chugai Licenses RAF-MEK Molecular Glue to InxMed
September 30, 2026
-
BUSINESS OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
-
REGULATORY Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
-
BUSINESS KM Biologics Eyes Plasma Product Capacity Expansion with Govt Backing
September 30, 2026
-
REGULATORY MHLW Panel Backs Easing Protopic Contraindication for Young Children
September 30, 2026
-
BUSINESS Japan Needs to Boost COVID Vaccine Uptake, Expert Says
September 30, 2026
-
REGULATORY PMDA Flags New Safety Risks with 3 Drugs
September 30, 2026
-
ORGANIZATION Generic Use Rate Hits Record 90.4% in April-June: JGA
September 30, 2026
-
BUSINESS Toho, Reprocell Tie Up on Cell Therapy Distribution in Japan
September 30, 2026
-
COLUMN Outside the Bubble: Lunch with Pharma Delegates
September 30, 2026
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…